6 completed, 1 active not recruiting. 7 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 6, Active not recruiting 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Dermatitis, Allergic Contact: new trials by email Literature Review of Dermatitis, Allergic Contact trials Research Report on Dermatitis, Allergic Contact
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation Squaric Acid Dibutyl Ester, Known patch test allergens, Dupilumab - Skin Inflammation, Allergic Contact Dermatitis | Phase 2 / Phase 3 | Active not recruiting | Wei-Che Ko | 45 | 2022-11-15 | 2026-06-09 |
| Evaluation of EB01 Cream for the Treatment of Chronic Allergic Contact Dermatitis EB01 Cream Placebo, EB01 Cream 0.2%, EB01 Cream 1.0% - Allergic Contact Dermatitis | Phase 2 | Completed | Edesa Biotech Inc. | 211 | 2019-10-15 | 2024-11-14 |
| Safety, Tolerability, and Efficacy of 21 Days Dermal Application of MRX-6 on Mild to Moderate Contact Dermatitis MRX-6, Steroid - Allergic Contact Dermatitis | Phase 1 / Phase 2 | Completed | Hadassah Medical Organization | 13 | 2011-03-01 | 2015-04-21 |
| Study of the Intradermal Injection of rHuPH20 or Placebo in Participants With Nickel Allergic Contact Dermatitis rHuPH20, Placebo - Dermatitis, Allergic Contact | Phase 2 | Completed | Halozyme Therapeutics | 22 | 2009-06-23 | 2021-12-17 |
| Study of Apremilast in Atopic or Contact Dermatitis Apremilast - Atopic Dermatitis, Allergic Contact Dermatitis | Phase 2 | Completed | Tufts Medical Center | 10 | 2009-06-01 | 2010-12-20 |
| Clinical Evaluation of the 3 Allergens: Methyldibromoglutharonitrile, Parthenolide and Goldnatriumthiosulphate Goldnatriomthiosulphate, MDBGN, parthenolide - Allergic Contact Dermatitis | Phase 2 | Completed | Mekos Laboratories AS | 60 | 2005-04-01 | 2006-02-27 |
| Clinical Evaluation of Bacitracin bacitracin (allergen) - Allergic Contact Dermatitis | Phase 2 | Completed | Mekos Laboratories AS | 20 | 2005-04-01 | 2005-10-19 |
Dermatitis (2) · Eczema (2) · Dermatitis, Atopic (1) · Dermatitis, Contact (1)
Hypersensitivity (7) · Hypersensitivity, Delayed (7) · Immune System Diseases (7) · Skin Diseases (7) · Skin Diseases, Eczematous (7) · Skin and Connective Tissue Diseases (7) · Dermatitis, Contact (6) · Dermatitis (5) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Genetic Diseases, Inborn (1) · Hypersensitivity, Immediate (1) · Skin Diseases, Genetic (1)
1,2-dibromo-2,4-dicyanobutane (1) · Adalimumab (1) · Allergens (1) · Bacitracin (1) · Betamethasone Valerate (1) · Fluticasone (1) · Steroids (1) · Triamcinolone Acetonide (1) · Ustekinumab (1) · apremilast (1) · canakinumab (1) · dupilumab (1) · guselkumab (1) · parthenolide (1) · sarilumab (1)
Mekos Laboratories AS (2) · Edesa Biotech Inc. (1) · Hadassah Medical Organization (1) · Halozyme Therapeutics (1) · Tufts Medical Center (1) · Wei-Che Ko (1)
United States (5) · Canada (1) · Denmark (1) · Israel (1)
Alice B. Gottlieb, M.D., PhD. (1) · Ikeadi M Ndukwu, M.D., MPH (1) · Joseph Fowler, Prof. (1) · Klaus E Andersen, Prof. (1) · Wei-Che Ko, MD (1) · Yuval Ramot, MD (1)